Kimberly-Clark Corporation (KMB) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is a moderate beat or in-line print — consensus has been trimmed since Q1 to reflect known headwinds (DC fire, tough comp, input cost pressure), creating a manageable bar — but the back-half input cost wildcard ($150–170M gross incremental if oil stays ~$100/bbl) is the single biggest swing factor for the full-year guide.

Heading into Q2 2026, KMB faces a deliberately de-risked consensus bar: organic sales growth is expected at roughly 1.2% (vs. 2.5% in Q1), reflecting the company's own guidance for growth "slightly below Q1" due to the toughest prior-year comp of the year (+4% enterprise, +5% North America volume in Q2 2025) and a ~$20M top-line headwind from the California distribution center fire.

Management's tone since Q1 has been constructive but cautious — the Kenvue integration is progressing well (40+ workstreams, 400+ people, post-close org structure announced April 15), and at the Deutsche Bank conference in June, CEO commentary escalated to "the closer you look, the better it gets" on the deal. However, the company explicitly flagged ~$50M of incremental bottom-line pressure in Q2 from Middle East-related input costs and the DC fire, and declined to update full-year guidance pending more clarity on oil prices.

Estimate revisions since the Q1 print have been modestly negative — Q2 organic sales consensus slipped from ~1.8% to ~1.2% and adjusted EPS from ~$1.64 to ~$1.62 — tracking management's cautious Q2 framing rather than diverging from it, which limits downside surprise risk.

The stock has re-rated sharply since Q1 earnings (+9.3% vs. XLP +2.1%, SPY +6.5%), driven by Kenvue deal confidence and multiple expansion rather than estimate upgrades, leaving KMB trading near the top of its post-announcement range and pricing in a clean execution story.

The key wildcard is whether management updates full-year guidance on the Q2 call: if oil has moderated and the $150–170M back-half cost risk is partially mitigated, a guidance raise or narrowing of the range could be a meaningful positive catalyst; conversely, any formal guidance cut would likely reverse the stock's recent outperformance.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus has set a low bar for Q2 organic growth (~1.2% vs. 2.5% in Q1), reflecting known headwinds;

adjusted EPS is the bigger swing factor — the $50M Q2 cost headwind (Middle East + DC fire) is largely in the number, but any upside on volume/mix or cost recovery could drive a beat.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of latest available (August 2026). Q2 2026 consensus organic growth of ~1.2% reflects the as-of 5/3/26 baseline of 1.79% revised down to 1.18% latest. Adj. EPS excludes discontinued operations (IFP segment reported as discontinued).

Table 2 — Beat/Miss History (Last 8 Quarters)

Top 2 KPIs: Organic Net Sales Growth (%) and Adjusted EPS — Excl. Discontinued Operations ($)

Pattern: KMB has beaten organic sales consensus in 5 of the last 6 quarters where data is available, with the two misses (Q3 2024, Q1 2025) coinciding with periods of category softness; the recent streak of beats (Q2 2025 through Q1 2026) reflects the company's volume/mix momentum outpacing a conservative sell-side. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year guidance was reaffirmed at Q1 earnings (April 28) and has not been formally revised since; however, management introduced a

significant unquantified back-half risk ($150–170M gross incremental input costs if oil stays ~$100/bbl) that is not yet in the guidance range, making the Q2 call a critical update point on whether that risk has materialized or moderated.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly lower since the Q1 print — Q2 organic growth consensus slipped ~60 bps and EPS ~$0.02 — tracking management's cautious Q2 framing;

full-year estimates are essentially flat, suggesting the Street is holding the line on the FY story pending clarity on back-half input costs.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of May 3, 2026 (5 trading days post Q1 earnings on April 28, 2026). The modest downward drift in Q2 estimates tracks management's own cautious framing; the FY story is largely intact, with the Street waiting for Q2 commentary on back-half input cost resolution before making larger revisions.

5. Stock Performance

Key Takeaway: KMB has significantly outperformed since Q1 earnings (+9.3% vs. XLP +2.1%, SPY +6.5%), driven primarily by

multiple re-rating on Kenvue deal confidence rather than estimate upgrades — the stock's run from ~$98 to ~$114 has outpaced the modest downward drift in consensus, suggesting sentiment and deal optionality are doing the heavy lifting.

KMB vs. XLP (Consumer Staples ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (April 28, 2026). Source: Stock Price Data.

Sector ETF: XLP (Consumer Staples Select Sector SPDR Fund) — appropriate for KMB's consumer staples / personal care sub-sector.

Key observations: KMB's outperformance accelerated in two distinct waves — (1) a gradual grind higher through May–early June as Kenvue integration confidence built, and (2) a sharp re-rating in late June through early July (stock moved from ~$97 to ~$115) coinciding with the Deutsche Bank conference (June 3) where management escalated Kenvue deal rhetoric to "the closer you look, the better it gets." The stock has since pulled back modestly to ~$108 as of August 3, likely reflecting pre-earnings caution and the broader XLP softness. Analyst price targets have been revised upward (Piper Sandler to $121 Overweight; UBS to $115 Neutral; Wells Fargo to $110 Equal Weight), with consensus PT around $115–116, suggesting limited near-term upside at current levels absent a positive guidance update.

6. Peer Commentaries — Read-Through (Last 60 Days, Q2 2026 Relevant)

Key Takeaway: Peers reporting Q2 2026 results (PG, Unilever, Church & Dwight, Newell, Clorox) paint a broadly constructive picture for KMB —

volume-led growth is alive and well in personal care and North America, category growth is tracking 2–2.7%, and input cost inflation is a shared headwind being managed through productivity and pricing — all consistent with KMB's own setup.

Note: Only commentary from peers' Q2 2026 earnings calls and post-Q1 2026 conferences (June–August 2026) is included below, as these reflect the current reporting quarter environment relevant to KMB's Q2 2026 print.

Procter & Gamble (PG) — Q4 FY2026 Earnings (July 29, 2026)

Read-through: Broadly positive for KMB's North America personal care and diaper businesses.

• North America consumer: PG noted North America organic sales were down 1% in Q4 FY2026 (April–June 2026) with a "notable disconnect between sell-out and sell-in" — consumption was +2% but sell-in was -1% due to retailer inventory reductions. This suggests underlying demand is healthier than shipments, a positive read-through for KMB's Q2 volume/mix.
• Baby care / diapers: PG returned to volume and value share growth on tape diapers after adjusting value competitiveness. In China, baby care grew 20% and gained share despite -15% birth rate declines. PG is the #1 baby care brand in China. This is a mixed read for KMB — PG's diaper recovery in the US means a more competitive environment, but strong China baby care growth is a positive read-through for KMB's Korea/Asia diaper momentum.
• Input cost inflation: PG guided to a ~$1B after-tax cost headwind for FY2027 (starting July 2026), assuming $90/bbl Brent crude, with most impact in H1 FY2027 (calendar H2 2026). This directly validates KMB's flagged $150–170M back-half risk and suggests the industry-wide cost pressure is real and front-loaded.
• Category growth: PG expects markets to deliver 1–3% local currency value growth for FY2027, with current run rate "roughly in the middle" (~2%). This aligns with KMB's updated 2.5% category growth assumption.
• Family care (tissue): PG's family care (Charmin/Bounty) was down for the year and the quarter, with management noting price points got "too far away" from private label in some channels. PG is reactivating its vertical portfolio. This is a modest negative read-through for KMB's tissue-adjacent positioning but KMB has largely exited tissue (IFP divestiture).

Unilever (ULVR) — Q2 2026 Earnings (July 28, 2026)

Read-through: Strongly positive for KMB's volume/mix growth thesis and personal care momentum.

• Volume growth: Unilever delivered its "best quarterly volume performance since 2010" in Q2 2026 — underlying sales growth of 5.8% with volume up 5.5%. This is a strong positive read-through for category health in personal care and home care, directly relevant to KMB's personal care segments.
• North America: North America "continues to outperform," growing 2.6% with 4.4% volume in Q2, led by deodorants, skin cleansing, and prestige beauty. This validates KMB's North America personal care recovery narrative.
• Emerging markets: Emerging markets grew 8.3% in Q2 with 7.4% volume. Brazil returned to strong volume-led growth; Indonesia grew 7%; India up 10%. These are direct read-throughs for KMB's International Personal Care segment, which has flagged Brazil double-digit growth and Indonesia recovery as key drivers.
• Input cost inflation: Unilever expects ~€850M of commodity inflation for FY2026 (center point), with ~€550M in H2 2026. Gross margins declined 70 bps YoY in H1 but are expected to hold at ~46.8% in H2 as pricing lands. This confirms the industry-wide cost headwind but also shows it is manageable with pricing and productivity.
• Pricing: Pricing was only 0.2% in Q2 but expected to "lead growth" in H2 as commodity-related pricing lands. Unilever has ~90% of revenue at its desired relative pricing level. This is a positive read-through for KMB's PNOC discipline and pricing toolkit.

Church & Dwight (CHD) — Q2 2026 Earnings (July 31, 2026)

Read-through: Positive for category growth and consumer resilience; mixed on promotional environment.

• Category growth: CHD's largest categories grew 2.7% in Q2, exceeding their ~2% expectation. CHD raised its full-year organic sales outlook to 4–5% (from 3–4%), driven by broad-based volume growth of 4.3%. This is a positive read-through for KMB's category growth assumption of ~2.5%.
• Consumer resilience: "Consumer spending remains resilient" — CHD noted higher elasticities when products go on promotion, but their value-positioned brands are holding share. This is consistent with KMB's good-better-best strategy and innovation-led volume growth.
• Input costs: CHD's latest inflation outlook is ~$30M (assuming $90/bbl crude), fully mitigated through productivity. CHD expects ~$15M of Phase 2 tariff refund benefits in H2 2026. Smaller scale than KMB but confirms the cost environment is manageable with the right toolkit.
• Gross margin: CHD's adjusted gross margin was 45.4% in Q2, up 40 bps YoY, with full-year expansion now guided at 100–120 bps. This is a positive read-through for KMB's own gross margin expansion trajectory.

Clorox (CLX) — Q4 FY2026 Earnings (August 3, 2026)

Read-through: Cautionary on category growth and input costs; less directly relevant to KMB's personal care focus.

• Category growth: CLX expects categories to remain "muted" in FY2027, consistent with the flat-to-up-1% range seen in FY2026. CLX's categories (cleaning, litter, food) are more discretionary-adjacent than KMB's personal care focus, so this is a partial read-through at best.
• Input cost inflation: CLX guided to >$200M of inflation for FY2027 (more than double historical range), assuming $90/bbl Brent. Inflation is "more persistent" and extends beyond oil to ocean freight, trucking, and supplier costs. This is a direct validation of KMB's back-half cost risk narrative.
• Gross margin: CLX expects to start recovering gross margin in H2 FY2027 but won't fully recover for the full year. The GOJO acquisition adds ~0.5 pts of gross margin dilution. This is a cautionary read-through — if CLX (with a simpler portfolio) is struggling to recover margins, KMB's path requires strong productivity execution.
• Promotional environment: CLX expects a "continued elevated promotional environment" in FY2027, in line with pre-COVID levels. This is consistent with KMB's use of targeted promotion for trial and its PNOC discipline.

Newell Brands (NWL) — Q2 2026 Earnings (July 31, 2026)

Read-through: Positive on North America consumer recovery; limited direct read-through to KMB's core categories.

• North America recovery: NWL returned to year-over-year growth for the first time in 4+ years in Q2 2026, with US net sales up ~5% — the first domestic growth since COVID. Baby products (Graco, Nook) delivered double-digit sales growth. This is a positive read-through for North America consumer demand broadly.
• Input cost inflation: NWL's inflation outlook rose from ~$100M to ~$200M for 2026, with $50M of the increase occurring since the last earnings call. This is the most dramatic cost escalation among peers and reinforces the severity of the Middle East-driven cost environment.
• Category trends: NWL's categories were essentially flat in Q2 (vs. -2% initial assumption), with the US outperforming EMEA. The company remains cautious on H2, assuming -1% category decline for the full year. Less relevant to KMB's personal care categories but confirms the bifurcated consumer environment.

PG Deutsche Bank Conference (June 3, 2026) — Pre-Quarter Commentary

Read-through: Relevant as a mid-quarter check on the consumer and cost environment heading into Q2 2026.

• US consumer: PG noted the US consumer has been "relatively stable" consuming at 2–3% across categories over 12-week rolling periods, with volatility from event timing and short-term wallet shocks (e.g., $6 gas prices). PG believes it can help grow the market back to 3%+ over 12–18 months through innovation-based pricing and penetration growth.
• Baby care / diapers: PG described US baby care as a "tale of two cities" — outside the US, growing sales and share; in the US, heavy short-term price competition. PG has returned diapers to share growth in the last 4–6–8 week periods. This is a mixed read for KMB's Huggies — competitive intensity in US diapers is real, but KMB has been gaining share for two consecutive years.
• Input costs: PG flagged ~$150M after-tax headwind for FY2026 from Middle East-related costs, with "almost all" in Q4 FY2026 (April–June 2026). Surfactants (highly oil-sensitive) were specifically called out, with the Strait of Hormuz closure constraining ~20% of global primary feedstock. This is directly relevant to KMB's nonwovens and oil-linked input cost exposure.

Peer Read-Through Summary Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the

escalating management confidence on the Kenvue acquisition (Deutsche Bank conference, June 2026), which has been the primary driver of the stock's re-rating; the secondary development is the unresolved back-half input cost risk from Middle East oil prices, which will be the key focus of the Q2 call.

• August 4, 2026 — Q2 2026 Earnings Release (today): KMB reports Q2 2026 results. Key focus: (1) organic sales growth vs. "slightly below Q1" guidance, (2) update on back-half input cost risk ($150–170M flagged at Q1), (3) any formal guidance revision, (4) Kenvue integration progress and expected close timing.
• July 7, 2026 — Earnings Date Announcement: KMB confirmed Q2 2026 results to be announced August 4, 2026. Routine press release; no new information.
• June 2026 — Deutsche Bank Global Consumer Conference: Management escalated Kenvue deal rhetoric to "the closer you look, the better it gets," citing underdeveloped Kenvue categories (100M US allergy sufferers), strong hidden international performance (EMEA, Latin America performing as well as KMB's best markets over 5 years), near-term e-commerce revenue synergies (KMB ~700 bps higher e-commerce share vs. offline; Kenvue is the reverse), and geographic distribution gaps (Kenvue multi-billion dollar business in Europe and ~3M distribution points in India; KMB multi-billion dollar business in Mexico and Korea). Post-close leverage expected at ~2.9x EBITDA, declining to ~2x within 24 months.
• Implication: This conference was the primary catalyst for the stock's late-June re-rating from ~$97 to ~$115.
• June 17, 2026 — Piper Sandler Raises Target to $121 (Overweight): Piper Sandler boosted its price target from $115 to $121 and maintained Overweight, the most bullish major analyst action since Q1 earnings. Reflects growing conviction on Kenvue deal value creation.
• May 28, 2026 — Deutsche Bank Conference Webcast Announcement: KMB announced it would webcast its Deutsche Bank presentation, signaling management's intent to use the conference as a key investor communication vehicle for the Kenvue deal thesis.
• May 14, 2026 — Annual Meeting Results (8-K): Shareholders elected all directors, approved executive pay, and rejected an independent chair proposal. No material governance changes; confirms board stability heading into the Kenvue close.
• May 5, 2026 — Controller Departure (8-K): Andrew Scribner (VP & Controller / Principal Accounting Officer) announced departure effective May 22, 2026. CFO Nelson Urdaneta assumed interim PAO role.
• Implication: Routine departure; no red flags given the interim nature and CFO coverage, but worth monitoring for a permanent replacement announcement.
• April 29, 2026 — Barclays Americas Select Conference: KMB presented at Barclays conference shortly after Q1 earnings. Likely reinforced Q1 messaging; no material new disclosures identified.
• April 28, 2026 — Q1 2026 Earnings (Beat + Reaffirm): KMB beat on both EPS and revenue; reaffirmed full-year guidance; flagged $50M Q2 headwind and $150–170M potential back-half input cost risk (not in guidance); California DC fire headwind of ~$20M top-line / 70–80 bps NA in Q2. Volume/mix growth accelerated to 3% (9th/10th consecutive quarter).
• Implication: Set the bar for Q2 and established the key risk (back-half costs) that will dominate the Q2 call.
• Analyst Consensus (as of August 2026): 16 analysts covering KMB; consensus Hold (1 Sell, 11 Hold, 4 Buy). Average 12-month price target ~$115–116. Highest target $162 (outlier); lowest $90. UBS raised to $115 Neutral (post-Q1); Wells Fargo raised to $110 Equal Weight (July 8); Deutsche Bank holds $109 Hold. Limited upside priced in at current ~$108 levels.

8. Insider Transaction Activity

Key Takeaway: No open-market buys since Q1 earnings; the only activity is two small post-earnings sales by the President of International Personal Care (Katy Chen) and the departing Controller (Andrew Scribner) —

nothing unusual in size or clustering, and the Scribner sale is consistent with his announced departure. The absence of insider buying at current levels is notable given the stock's run, but not alarming.

Source: SEC Form 4 Filings (Insider Transaction Data). Window: April 28 – August 3, 2026 (since Q1 2026 earnings). Open-market transactions only (Form 4 code S). No open-market purchases filed in the period. No 10b5-1 plan initiations identified.

Assessment: The two Katy Chen sales are small in dollar terms (~$295K combined) relative to her retained position (6,500+ shares) and are consistent with post-earnings window selling. The Scribner sale is departure-driven. No clustered buying or unusual sale patterns. The absence of insider buying at $98–100 (post-Q1 levels) is worth noting — management did not use the post-earnings dip to add shares — but this is not unusual for a company in the midst of a major acquisition where insiders may be restricted or cautious about signaling.